Belite Bio, Inc (BLTE)
Upgrades & Downgrades
Latest BLTE news
3 Breakout Growth Stocks to Buy for the Long Haul
9 January 2023
These three have had big-time share gains backed up by breakthrough science.
These Are the 10 Best-Performing IPOs in 2022 Through October
16 November 2022
The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
3 October 2022
Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases. The post Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Perf...
Belite Bio, Inc's (BLTE) CEO Tom Lin on Q2 2022 Results - Earnings Call Transcript
13 August 2022
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Tom Lin – Chief Executive Officer Nathan Mata – Chief Scientific Officer Hao-Yuan Chuang...
Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
1 August 2022
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a...